BioPharma DiveOriginal article
Bristol Myers dips on ‘confounding’ lung drug results
Phase 3MixedadmilparantNegative
AI Analysis
Summary
Bristol Myers' idiopathic pulmonary fibrosis drug admilparant showed mixed Phase 3 results, with only the lower of two tested doses meeting the primary endpoint, raising questions about the therapy's viability.
Clinical Trial Data
Phase
Phase 3
Primary Endpoint
Not Met
Outcome Details
Only the lower of two tested doses met the trial's main objective
Importance:7/10
Sentiment:
-0.65
clinical trialidiopathic pulmonary fibrosisdose-responsefailed primary endpoint
Related Companies
Read the original article
Published by BioPharma Dive on October 12, 2026 3:35 PM